Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2017 07:30 ET | Source: Ocera Therapeutics, Inc.

Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical study findings of OCR-002 (ornithine...
August 23, 2017 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study...
March 27, 2017 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera to Present at the 16th Annual Needham Healthcare Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
March 10, 2017 06:00 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 10, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
March 08, 2017 08:05 ET | Source: Ocera Therapeutics, Inc.

Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

IV OCR-002 statistically significantly normalized ammonia faster than standard of care Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms Ocera plans...
February 28, 2017 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
January 30, 2017 07:00 ET | Source: Ocera Therapeutics, Inc.

Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

Primary and Secondary Endpoints Showed Trend and Dose-Related Clinical Benefit Although Not Statistically Significant Ammonia Scavenger OCR-002 Demonstrated Statistically Significant Reduction in...
November 02, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
October 24, 2016 09:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that clinical data from STOP-ALF, a Phase 2a clinical...
September 21, 2016 16:05 ET | Source: Ocera Therapeutics, Inc.

Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced completion of enrollment in STOP-ALF, a Phase...

Next Page keyboard_arrow_right